Chroma Medicine is a biotechnology company developing therapies that change how genes behave without cutting or rewriting the DNA itself, an approach broadly known as epigenetic editing. Instead of altering the genetic code the way traditional CRISPR therapies do, Chroma’s platform adds or removes small chemical tags on DNA and its surrounding proteins to turn genes up or down, much like dimming a light switch rather than ripping out the wiring. The approach sits at the frontier of a rapidly growing field that has produced its first clinical data in humans and is attracting attention across oncology, infectious disease, and neurology.
What Epigenetic Editing Actually Does
Every cell in your body carries essentially the same DNA, yet a liver cell behaves nothing like a brain cell. The difference comes down to which genes are switched on or off, and that switching is controlled by chemical marks layered on top of the DNA sequence. Small methyl groups attached directly to DNA, and various modifications to the histone proteins that DNA wraps around, collectively determine whether a gene is active, quiet, or completely silenced. These marks are what biologists call the epigenome.
Traditional CRISPR gene editing uses a molecular scissor (the Cas9 enzyme) to physically cut DNA strands, relying on the cell’s repair machinery to introduce a desired change. That works, but cutting DNA carries inherent risks: the broken ends can rejoin incorrectly, chunks of chromosomes can be lost, or unrelated genes nearby can be disrupted. Epigenetic editing sidesteps all of that. It uses a deactivated version of Cas9, called dCas9, which has had its cutting ability disabled. The dCas9 still travels to a precise spot on the genome guided by a short RNA sequence, but instead of cutting, it carries an enzyme that writes or erases a chemical mark at that location. The underlying DNA sequence stays intact.1Current Opinion in Biomedical Engineering. Editing without breaking: Sustained gene control via epigenetic rewriting
The Two Sides of the Toolkit
Epigenetic editing tools fall into two broad categories: writers that add silencing marks and erasers that remove them. Chroma Medicine and other companies in this space use both, depending on whether a disease calls for turning a harmful gene off or a beneficial gene back on.
On the silencing side, researchers fuse dCas9 to methyltransferase enzymes, which attach methyl groups to DNA. When these methyl tags land on a gene’s promoter region, they act like a “do not read” sign, preventing the cell’s machinery from transcribing the gene into protein. One well-characterized approach links dCas9 to a combination of the Dnmt3a methyltransferase and its partner Dnmt3L. Studies have shown that a single guide RNA directing this fusion protein to a specific promoter can produce efficient and widespread methylation across the targeted region.2PubMed Central. Efficient targeted DNA methylation with chimeric dCas9–Dnmt3a–Dnmt3L methyltransferase An alternative design, called SunTag, attaches multiple copies of the methyltransferase enzyme to a single dCas9 molecule to boost the concentration of the writer enzyme at the target site.3PubMed Central. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A
On the activation side, the same SunTag architecture has been adapted to recruit TET1, an enzyme that strips methyl groups off DNA. In laboratory tests, this system achieved demethylation at more than half the sites it was aimed at, with several loci showing over 90% removal of methyl marks. That demethylation translated into meaningful increases in gene activity, boosting expression of associated genes anywhere from roughly two-fold to fifty-fold in both cell cultures and in living mouse embryos.4PubMed. Targeted DNA demethylation in vivo using dCas9-peptide repeat and scFv-TET1 catalytic domain fusions This is the kind of versatility that makes epigenetic editing appealing: the same basic platform can silence or reactivate genes depending on which enzyme is bolted onto the guide system.
The Hepatitis B Breakthrough
The most striking clinical milestone so far for epigenetic editing as a category came not from Chroma Medicine but from Tune Therapeutics, a company working in the same space. Their candidate, TUNE-401, targets chronic hepatitis B, a disease that has stubbornly resisted cure because the virus hides a tiny ring of DNA, called cccDNA, inside liver cell nuclei. Conventional antivirals can suppress viral replication, but the cccDNA persists as a reservoir that can reactivate the infection whenever treatment stops.
TUNE-401 takes a fundamentally different approach. Rather than attacking the virus’s replication machinery, it deposits silencing chromatin marks directly onto the cccDNA, shutting down the viral genome’s ability to produce new viral components without touching the patient’s own DNA. Early clinical results showed that multiple patients achieved durable reductions of more than 95% in a key viral RNA marker and more than 99% in another viral protein marker. Three of ten patients in the highest-dose groups reached complete negativity for both markers after just a single dose, which the investigators described as unprecedented for a single-agent, single-dose therapy.5AJMC. First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA
These results matter well beyond hepatitis B. They represent proof that epigenetic silencing can work inside a human body with a single administration, durably suppressing a target over weeks to months. If the effect holds up in larger trials and over longer follow-up periods, it validates the core promise of the entire field, including Chroma’s platform.
Upgrading Cancer Immunotherapy
One of Chroma Medicine’s most publicly discussed applications involves improving CAR T cell therapy, the approach where a patient’s own immune cells are engineered to attack tumors. CAR T cells are powerful against certain blood cancers, but they tend to become exhausted in the hostile environment around solid tumors, losing their cancer-killing ability over time. Two genes closely associated with this exhaustion are PDCD1 (which encodes the PD-1 “braking” receptor) and LAG3 (another immune checkpoint). Standard practice has been to knock these genes out with traditional CRISPR cutting, but cutting two genes simultaneously in the same cell raises the risk of chromosomal rearrangements, where severed DNA ends from different chromosomes fuse together incorrectly.
Chroma’s epigenetic approach silences both PDCD1 and LAG3 by depositing methyl marks on their promoters, shutting them down without ever breaking a DNA strand. Published work shows that these epigenetically modified CAR T cells were functionally indistinguishable from unedited parent cells across a range of laboratory tests, meaning the silencing did not harm the T cells’ normal capabilities.6Molecular Therapy. Multiplexed targeted epigenome editing of primary human and CAR T cells Separately, research comparing this approach head-to-head with traditional Cas9 cutting found that multiplex epigenetic silencing did not cause genomic rearrangements above background levels, whereas Cas9-based multiplex editing did.7Blood. Durable Multiplex Epigenetic Editing for Generation of Allogeneic CAR T without Chromosomal Rearrangements
That safety distinction could prove decisive for the next generation of off-the-shelf CAR T products, which require editing multiple genes at once, typically knocking out immune markers so that donor T cells do not trigger rejection when infused into a different patient. Each additional gene edited with a nuclease multiplies the probability of a translocation event. Epigenetic silencing offers a path to editing three, four, or more genes simultaneously without stacking that risk.
Reactivating Tumor Suppressors
Cancer is not only about overactive growth signals. Many tumors survive because genes that normally restrain cell growth have been epigenetically silenced, buried under methyl marks that the cancer cell benefits from keeping in place. Traditional epigenetic drugs, like the demethylating agents used to treat certain blood cancers, strip methyl marks across the entire genome, which can cause widespread side effects. Epigenetic editing promises to reactivate those sleeping tumor-suppressor genes one at a time, leaving the rest of the genome alone.
In hepatocellular carcinoma (liver cancer) cell lines, researchers have used CRISPR-based activation systems to simultaneously turn back on four silenced tumor-suppressor genes. The combined reactivation reduced cell growth, blocked the cells’ ability to migrate, and impaired other hallmarks of aggressive cancer behavior.8PubMed Central. Epigenetic reactivation of tumor suppressor genes with CRISPRa technologies as precision therapy for hepatocellular carcinoma In breast cancer, a separate group used a dCas9-TET1 fusion to demethylate and reactivate a microRNA called miR-200c, which normally suppresses the process by which cancer cells become more invasive. Restoring miR-200c led to decreased expression of genes driving that invasive transition in both less-aggressive and highly aggressive breast cancer cell lines.9Scientific Reports. CRISPR/dCas9-TET1–mediated epigenetic editing reactivates miR-200c in breast cancer cells
These results remain in early laboratory stages, not in patients. But they illustrate a core advantage of the epigenetic approach in oncology: the ability to precisely reawaken the cell’s own tumor-fighting machinery rather than adding foreign genes or broadly toxic drugs.
Cholesterol, Metabolic Disease, and Single-Dose Durability
Outside of cancer and infectious disease, one of the most compelling demonstrations of epigenetic editing’s potential involves cholesterol regulation. A study using mRNA-encoded epigenetic silencing tools delivered via lipid nanoparticles targeted the Pcsk9 gene in mice, the same gene that blockbuster injectable cholesterol drugs like evolocumab and alirocumab are designed to block at the protein level. A single intravenous dose of the epigenetic editor reduced circulating PCSK9 protein by roughly 83% and lowered LDL cholesterol by about 51%, with both effects persisting for at least 180 days.10The Innovation. mRNA-engineered CRISPR-Cas epigenetic editors enable durable and efficient gene silencing in vivo
That durability after a single dose is remarkable and distinguishes epigenetic editing from most existing approaches. Current PCSK9-inhibiting drugs require injections every two to four weeks. Even siRNA-based therapies that silence PCSK9 at the RNA level, like inclisiran, need dosing every six months. An epigenetic approach that lasts half a year or longer from a single administration could reshape how chronic metabolic conditions are managed, potentially turning lifelong medication schedules into infrequent treatments.
The mouse results also highlight a key feature of epigenetic changes: they can be durable because the cell’s own maintenance machinery tends to preserve methyl marks through cell division. Research in yeast has shown that specific DNA sequences help maintain inherited silencing states across generations of cell replication, suggesting that well-placed epigenetic marks are not easily lost.11PubMed Central. DNA sequence-dependent epigenetic inheritance of gene silencing and histone H3K9 methylation Whether that same stability translates reliably to human therapeutics at every target gene remains an open question, but early clinical and preclinical data are encouraging.
Neurological and Psychiatric Disorders
The brain presents unique challenges and opportunities for epigenetic therapy. Many neurological and psychiatric conditions, including chronic pain syndromes, certain forms of epilepsy, and neurodegenerative diseases, involve genes that are abnormally turned on or off in specific populations of neurons. Because these conditions often result from gene misregulation rather than gene mutation, they are natural candidates for epigenetic correction. A recent review characterized epigenetic editing as a promising approach for neurological and neuropsychiatric disorders, enabling precise and lasting modification of the genes involved.12PubMed Central. Epigenetic Editing in Neurological and Neuropsychiatric Disorders: Pioneering Next-Gen Therapeutics for Precision Gene Control
The biggest practical hurdle is delivery. Getting large molecular complexes across the blood-brain barrier and into the right neurons is vastly more difficult than reaching liver cells, which naturally take up lipid nanoparticles from the bloodstream. Chroma and other companies in this space have not yet announced clinical-stage neurological programs, but the foundational science is moving rapidly in preclinical models. Pain-related targets and repeat-expansion disorders, where toxic gene products accumulate because a mutated gene is stuck in the “on” position, are among the conditions receiving the most attention.
Off-Target Risks and Delivery Hurdles
No editing technology is perfectly precise, and epigenetic editing is no exception. Whole-genome sequencing of cells treated with dCas9 methyltransferases has revealed that while the tools do not cause global changes to the methylation landscape, they can produce more than a thousand off-target regions where methylation is altered beyond the intended site.13GigaScience. Genome-wide determination of on-target and off-target characteristics for RNA-guided DNA methylation by dCas9 methyltransferases Whether those off-target marks cause meaningful biological consequences depends heavily on where they land and in what tissue. Most may fall in inactive regions of the genome and have no practical effect, but the concern is serious enough that every therapeutic candidate needs rigorous genome-wide profiling before advancing to patients.
Delivery is arguably the field’s most pressing bottleneck. The dCas9 fusion proteins used in epigenetic editing are large molecules, and getting them into cells efficiently while avoiding unwanted immune responses is a persistent engineering challenge. One approach packages the instructions as mRNA inside lipid nanoparticles, which has shown promise for liver-targeted applications (as in the cholesterol study mentioned earlier). But for organs beyond the liver, including the brain, lungs, and kidneys, the delivery problem remains largely unsolved. Researchers have noted that the large size of dCas9 fusion proteins, the need to deliver multiple components simultaneously, and the potential for immune reactions against the delivery vehicle itself are all major obstacles.14Methods in Molecular Biology. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA
There is also the question of reversibility, which cuts both ways. Because epigenetic marks can be erased by the cell’s own enzymes under certain conditions, an epigenetic edit might fade over time in rapidly dividing tissues, requiring re-dosing. In slowly dividing cells like neurons or hepatocytes, the marks tend to persist longer. Designing therapies that achieve the right duration of effect for each disease context, neither too fleeting nor irrevocably permanent, is a nuanced problem that the field is still working through.
How Regulators Are Adapting
Epigenetic editing therapies sit in a regulatory gray zone between traditional gene therapies and conventional drugs. They modify gene function, which puts them under the FDA’s gene therapy framework, but they do not alter the DNA sequence, which complicates the standard risk calculus that regulators use for nuclease-based approaches. The FDA has been developing more flexible regulatory pathways in recent years, including platform-based and risk-adapted frameworks designed to accommodate newer modalities like mRNA therapeutics and targeted editing tools.15Journal of Clinical Pharmacology. FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions
For companies like Chroma Medicine, how regulators classify epigenetic therapies will have practical consequences for clinical trial design, manufacturing standards, and long-term safety monitoring requirements. If regulators treat epigenetic editors as equivalent to nuclease-based gene therapies, companies will face the same intensive and expensive clinical development timelines. If a lighter-touch framework emerges that recognizes the lower genotoxic risk of non-cutting approaches, the path to patients could accelerate. The regulatory conversation is early, and no epigenetic editing therapy has yet received marketing approval, but the TUNE-401 hepatitis B data and Chroma’s advancing pipeline are beginning to force the question.
Where Chroma Fits in a Crowded Field
Chroma Medicine is not the only company pursuing epigenetic editing. Tune Therapeutics (whose hepatitis B data were discussed earlier) is a direct competitor. Larger gene therapy companies with nuclease-based platforms are also exploring epigenetic add-ons. Academic labs worldwide continue to publish new tool designs, delivery strategies, and disease-model results at a rapid pace. What distinguishes Chroma is its stated focus on building a broad, programmable platform rather than a single disease-specific therapy, aiming to address multiple conditions across oncology, metabolic disease, and beyond using the same underlying engineering.16The Innovation. Chroma Medicine: Next-Gen Epigenetic Breakthroughs in Healthcare
The platform approach matters because one of the biggest costs in biopharmaceutical development is reinventing manufacturing and safety testing for each new product. If a company can demonstrate that its core editing system is safe and deliverable once, and then swap in different guide RNAs to address different genes, the economics improve dramatically. That logic drove the success of mRNA vaccine platforms during the pandemic, and investors are betting that a similar dynamic could play out with epigenetic editors.
The field’s trajectory over the next few years will hinge on a handful of concrete questions: Can the hepatitis B silencing results from TUNE-401 hold up over twelve months and beyond? Will Chroma’s CAR T modifications translate into better patient outcomes in solid tumor trials? Can delivery technology advance fast enough to make non-liver tissues routinely accessible? And will regulators create a pathway that reflects the genuinely different risk profile of tools that leave DNA uncut? The answers will determine whether epigenetic editing joins gene therapy and mRNA technology as a pillar of next-generation medicine, or whether it remains a compelling idea that falls short in the clinic.